Conclusions:
The COG CT committee conducts innovative trials to improve patient
outcomes following autologous, allogeneic and immune effector cell
therapies. Relapse remains a significant cause of treatment failure, and
the CT committee strives to make further improvements through innovative
trials of new preparative regimen strategies, incorporation of
maintenance therapy, and by facilitating multicenter studies of relapsed
or refractory solid tumors with emerging cellular treatments such as
tumor specific lymphocytes52 or NK cell-based
therapies53. Supportive care for CT patients is also
critical, particularly for viral infections. A trial of CMV directed
prophylaxis will open within the year. In addition, COG has existing
infrastructure and CT expertise to explore multi-center trials
evaluating antigen specific T cells targeting
viruses,51 tumor-associated
antigens,54, 55 and to control viral infections and
malignancy in HCT patients. Finally, the broadening applicability of
CAR-T cells targeting CD19+/-CD22 and other combination targets in the
pediatric setting56 represents a unique opportunity
for the COG CT committee to support advanced phased clinical trials for
CAR-T approaches.
Author contributions: CLK and JEL wrote the paper, all authors
critically revised the paper and approved the final version.
Conflict of interest disclosure: JEL has a patent for GVHD biomarkers
and receives royalties from Viracor. CLK was on an advisory board for
Horizon Therapeutics.